To experimentally test the effects of p53 loss on CA and determine the sensitivity to TACC3 inhibition in cancer cells with p53 loss or mutation, we first used p53 null (p53−/−) derivatives of the non-CA cell line, MCF-7 which was generated via CRISPR-Cas9 (Fig. 4E). The gene discussed is TP53; the disease is cancer.